After a 48% fall since the start of the year, Pfizer (NYSE:PFE) shares are firmly in value stock territory. The fall in demand for Covid-19 vaccines has been weighing on the company’s share price.
The stock comes with a 6.35% dividend at today’s prices. But there are a few things UK investors should note before considering buying the stock for a passive income portfolio.
Payout
Let’s start with that dividend. UK investors should note that distributions from US companies – such as Pfizer – are subject to a 15% withholding tax.
As such, the yield I’d actually get from buying the stock at today’s prices would be more like 5.35%. There are other variables like exchange rates to consider as well, which can have an effect.
This doesn’t put me off buying the stock at the moment and owning US shares is a good way of diversifying a UK-based portfolio. But it’s something that’s worth considering.
The biggest risk with buying shares for passive income is the dividend being cut. And Pfizer noting that US vaccine rates have dropped from 70% to 20% now suggests there might be a danger of this.
It’s worth noting, though, that the dividend for March 2024 is higher than the average quarterly payout from this year. So the potential decline in vaccine sales doesn’t look like an immediate issue.
Long-term prospects
Value investing is about more than just dividends, though. It’s about how the underlying business is likely to perform relative to its price today.
Pfizer has a lot of features that give it good long-term prospects. Its scale gives it an advantage over smaller businesses when it comes to distribution and its technical expertise is difficult to replicate.
On top of this, it has a huge budget for research and development. With new drugs having a success rate of less than 1-in-10 from Phase 1 to full approval, this is important.
Warren Buffett notes that pharmaceuticals companies are difficult to evaluate accurately. This is true, but it didn’t stop Berkshire Hathaway from investing broadly in them in 2020.
Charlie Munger later revealed the reason for Berkshire’s investment was that it believed the stocks were good passive income opportunities. And I think that might be the case with Pfizer today.
Margin of safety
Pfizer is going all in on cancer treatments with its huge acquisition of Seagen. I don’t have the technical knowledge to assess how that will turn out, or the prospects for the rest of its pipeline.
It might be that I don’t need to, though. The company has some clear long-term advantages that should allow it to generate steady cash flows for investors.
The stock has struggled in 2023 as demand for Covid vaccines has faltered. But at today’s prices, I think the risk might well be worth it, even for UK investors.
The post A 6% yield but down 48%! Is this value stock now too cheap to ignore? appeared first on The Motley Fool UK.
5 Shares for the Future of Energy
Investors who don’t own energy shares need to see this now.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.
While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.
Open this new report — 5 Shares for the Future of Energy — and discover:
Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
How to potentially get paid by the weather
Electric Vehicles’ secret backdoor opportunity
One dead simple stock for the new nuclear boom
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
Here’s how spending £10k on cheap dividend shares could earn me £1,000 in annual passive income
5 reasons I think stocks and shares are truly the best for passive income
FTSE 100 forecasts predict a surge to 8,368 points! Time to start buying cheap shares?
How to invest £77 a week in a SIPP to aim for a million-pound nest egg
2 phenomenal FTSE dividend stocks I’d buy before 2024
Stephen Wright has positions in Berkshire Hathaway. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
